{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T16:12:38Z","timestamp":1781194358392,"version":"3.54.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,14]],"date-time":"2023-03-14T00:00:00Z","timestamp":1678752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"South African Heart Association"},{"name":"South African Medical Association"},{"DOI":"10.13039\/100002806","name":"Discovery Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002806","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000308","name":"Carnegie Corporation of New York","doi-asserted-by":"publisher","award":["B8749.RO1"],"award-info":[{"award-number":["B8749.RO1"]}],"id":[{"id":"10.13039\/100000308","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of the Witwatersrand"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cardiomyopathies are a heterogeneous group of cardiac muscle disorders that result in dilated, hypertrophic, or restrictive pathophysiological entities. Dilated cardiomyopathy (DCM) is the most common form in sub-Saharan Africa (SSA). However, population-specific research studies reporting the actual burden of DCM in this region are still lacking. Also, little is known about the genetic basis of DCM in this population, and genetic testing is still not readily accessible. This review describes the common pathogenic genes implicated in DCM globally and discusses the evidence-based management of patients with DCM. We also present a summary of studies describing genes implicated or associated with DCM in patients residing in SSA.<\/jats:p>","DOI":"10.1007\/s10741-023-10302-9","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T22:51:56Z","timestamp":1679871116000},"page":"879-892","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The genetic basis for adult-onset idiopathic dilated cardiomyopathy in people of African descent"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7210-1447","authenticated-orcid":false,"given":"Nqoba","family":"Tsabedze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4156-4801","authenticated-orcid":false,"given":"Michele","family":"Ramsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7157-0807","authenticated-orcid":false,"given":"Amanda","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3899-0313","authenticated-orcid":false,"given":"Quinn","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3769-4686","authenticated-orcid":false,"given":"Dineo","family":"Mpanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2709-2158","authenticated-orcid":false,"given":"Pravin","family":"Manga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,14]]},"reference":[{"key":"10302_CR1","doi-asserted-by":"publisher","unstructured":"Agbor VN, Essouma M, Ntusi NaB, Nyaga UF, Bigna JJ, Noubiap JJ (2018) Heart failure in sub-Saharan Africa: a contemporaneous systematic review and meta-analysis. Int J Cardiol 257. https:\/\/doi.org\/10.1016\/j.ijcard.2017.12.048","DOI":"10.1016\/j.ijcard.2017.12.048"},{"key":"10302_CR2","unstructured":"Steenekamp JH, Simson IW, Theron W (1992) Cardiovascular causes of death at Tshepong Hospital in 1 year, 1989\u20131990. A necropsy study. S Afr Med J 81(3)"},{"key":"10302_CR3","doi-asserted-by":"publisher","unstructured":"Stewart S, Carrington M, Pretorius S, Methusi P, Sliwa K (2011) Standing at the crossroads between new and historically prevalent heart disease: effects of migration and socio-economic factors in the Heart of Soweto cohort study. Eur Heart J 32(4).\u00a0https:\/\/doi.org\/10.1093\/eurheartj\/ehq439","DOI":"10.1093\/eurheartj\/ehq439"},{"key":"10302_CR4","doi-asserted-by":"publisher","unstructured":"Dokainish H, Teo K, Zhu J, Roy A, Alhabib KF, Elsayed A et al (2013) Heart failure in Africa, Asia, the Middle East and South America: the INTER-CHF study. Int J Cardiol 204. https:\/\/doi.org\/10.1016\/j.ijcard.2015.11.183","DOI":"10.1016\/j.ijcard.2015.11.183"},{"key":"10302_CR5","doi-asserted-by":"publisher","unstructured":"Callender T, Woodward M, Roth G, Farzadfar F, Lemarie JC, Gicquel S et al (2014) Heart failure care in low- and middle-income countries: a systematic review and meta-analysis. PLoS Med 11(8). https:\/\/doi.org\/10.1371\/journal.pmed.1001699","DOI":"10.1371\/journal.pmed.1001699"},{"key":"10302_CR6","doi-asserted-by":"publisher","unstructured":"Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P et al (2008) Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 29(2). https:\/\/doi.org\/10.1093\/eurheartj\/ehm342","DOI":"10.1093\/eurheartj\/ehm342"},{"key":"10302_CR7","doi-asserted-by":"publisher","unstructured":"Fatkin D, Johnson R, Mcgaughran J, Weintraub RG, Atherton JJ, Group CGCW (2017) Position statement on the diagnosis and management of familial dilated cardiomyopathy. Heart Lung Circ 26(11). https:\/\/doi.org\/10.1016\/j.hlc.2017.04.021","DOI":"10.1016\/j.hlc.2017.04.021"},{"key":"10302_CR8","doi-asserted-by":"publisher","unstructured":"Rosenbaum AN, Agre KE, Pereira NL (2020) Genetics of dilated cardiomyopathy: practical implications for heart failure management. Nat Rev Cardiol 17(5). https:\/\/doi.org\/10.1038\/s41569-019-0284-0","DOI":"10.1038\/s41569-019-0284-0"},{"key":"10302_CR9","doi-asserted-by":"publisher","unstructured":"Jordan E, Peterson L, Ai T, Asatryan B, Bronicki L, Brown E et al (2021) Evidence-based assessment of genes in dilated cardiomyopathy. Circulation 144(1). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.053033","DOI":"10.1161\/CIRCULATIONAHA.120.053033"},{"key":"10302_CR10","doi-asserted-by":"publisher","unstructured":"Tayal U, Ware JS, Lakdawala NK, Heymans S, Prasad SK (2021) Understanding the genetics of adult-onset dilated cardiomyopathy: what a clinician needs to know. Eur Heart J 42(24). https:\/\/doi.org\/10.1093\/eurheartj\/ehab286","DOI":"10.1093\/eurheartj\/ehab286"},{"key":"10302_CR11","doi-asserted-by":"publisher","unstructured":"Schultheiss HP, Fairweather D, Caforio ALP, Escher F, Hershberger RE, Lipshultz SE et al\u00a0 (2019) Dilated cardiomyopathy. Nat Rev Dis Primers 5(1). https:\/\/doi.org\/10.1038\/s41572-019-0084-1","DOI":"10.1038\/s41572-019-0084-1"},{"key":"10302_CR12","doi-asserted-by":"publisher","unstructured":"Shaboodien G, Spracklen TF, Kamuli S, Ndibangwi P, Van Niekerk C, Ntusi NaB (2020) Genetics of inherited cardiomyopathies in Africa. Cardiovascular diagnosis and therapy 10(2). https:\/\/doi.org\/10.21037\/cdt.2019.10.03","DOI":"10.21037\/cdt.2019.10.03"},{"key":"10302_CR13","doi-asserted-by":"publisher","unstructured":"Mcnally EM, Mestroni L. Dilated cardiomyopathy: genetic determinants and mechanisms. Circ Res. 2017;121(7). https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.309396","DOI":"10.1161\/CIRCRESAHA.116.309396"},{"key":"10302_CR14","doi-asserted-by":"publisher","unstructured":"Van Berlo JH, De Voogt WG, Van Der Kooi AJ, Van Tintelen JP, Bonne G, Yaou RB et al (2005) Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: do lamin A\/C mutations portend a high risk of sudden death? J Mol Med (Berl) 83(1). https:\/\/doi.org\/10.1007\/s00109-004-0589-1","DOI":"10.1007\/s00109-004-0589-1"},{"key":"10302_CR15","doi-asserted-by":"publisher","unstructured":"Ciarambino T, Menna G, Sansone G, Giordano M (2021) Cardiomyopathies: an overview. Int J Mol Sci 22(14). https:\/\/doi.org\/10.3390\/ijms22147722","DOI":"10.3390\/ijms22147722"},{"key":"10302_CR16","doi-asserted-by":"publisher","unstructured":"Adadi N, Radi FZ, Lahrouchi N, Hara L, Ratbi I, Elalaoui SC et al (2018) Inherited dilated cardiomyopathy in a large Moroccan family caused by LMNA mutation. Anatol J Cardiol 20(1). https:\/\/doi.org\/10.14744\/AnatolJCardiol.2018.69639","DOI":"10.14744\/AnatolJCardiol.2018.69639"},{"key":"10302_CR17","doi-asserted-by":"publisher","unstructured":"Fish M, Shaboodien G, Kraus S, Sliwa K, Seidman CE, Burke MA et al (2016) Mutation analysis of the phospholamban gene in 315 South Africans with dilated, hypertrophic, peripartum and arrhythmogenic right ventricular cardiomyopathies. Sci Rep 6. https:\/\/doi.org\/10.1038\/srep22235","DOI":"10.1038\/srep22235"},{"key":"10302_CR18","doi-asserted-by":"publisher","unstructured":"Sayed S, Idriss NK, Blann A, Sayyed HG, Raafat DM, Fouad D et al (2015) The number of GT(n) repeats in the hemeoxygenase-1 gene promoter is increased in pediatric heart failure but is unrelated to renal, antioxidant and anti-inflammatory markers. Pediatric cardiology 36(6). https:\/\/doi.org\/10.1007\/s00246-015-1146-0","DOI":"10.1007\/s00246-015-1146-0"},{"key":"10302_CR19","doi-asserted-by":"publisher","unstructured":"Mahjoub S, Mehri S, Ghazouani E, Ouarda F, Boussada R, Zaroui A et al (2010) HLA class II polymorphisms in Tunisian patients with dilated cardiomyopathy. Tissue Antigens 75(6). https:\/\/doi.org\/10.1111\/j.1399-0039.2009.01432.x","DOI":"10.1111\/j.1399-0039.2009.01432.x"},{"key":"10302_CR20","doi-asserted-by":"publisher","unstructured":"Mahjoub S, Mehri S, Ourda F, Boussaada R, Zouari B, Ben Arab S (2011) [Epidemiological study of the idiopathic dilated cardiomyopathy in Tunisia]. Ann Cardiol Angeiol (Paris) 60(4). https:\/\/doi.org\/10.1016\/j.ancard.2011.04.006","DOI":"10.1016\/j.ancard.2011.04.006"},{"key":"10302_CR21","doi-asserted-by":"publisher","unstructured":"Shaboodien G, Engel ME, Syed FF, Poulton J, Badri M, Mayosi BM (2009) The mitochondrial DNA T16189C polymorphism and HIV-associated cardiomyopathy: a genotype-phenotype association study. BMC Med Genet 10. https:\/\/doi.org\/10.1186\/1471-2350-10-37","DOI":"10.1186\/1471-2350-10-37"},{"key":"10302_CR22","unstructured":"Du Preez J, Matolweni LO, Greenberg J, Mntla P, Adeyemo AA, Mayosi BM (2018) The \u03b12CDel322\u2013325 adrenergic receptor polymorphism is not associated with heart failure due to idiopathic dilated cardiomyopathy in black Africans"},{"key":"10302_CR23","unstructured":"Woodiwiss AJ, Badenhorst D, Sliwa K, Brooksbank R, Essop R, Sareli P et al (2008) \u03b21- and \u03b12c-adrenoreceptor variants as predictors of clinical aspects of dilated cardiomyopathy in people of African ancestry"},{"key":"10302_CR24","doi-asserted-by":"publisher","unstructured":"Badenhorst D, Norton GR, Sliwa K, Brooksbank R, Essop R, Sareli P et al (2007) Impact of beta2-adrenoreceptor gene variants on cardiac cavity size and systolic function in idiopathic dilated cardiomyopathy. Pharmacogenomics J 7(5). https:\/\/doi.org\/10.1038\/sj.tpj.6500426","DOI":"10.1038\/sj.tpj.6500426"},{"key":"10302_CR25","doi-asserted-by":"publisher","unstructured":"Khogali SS, Mayosi BM, Beattie JM, Mckenna WJ, Watkins H, Poulton J (2001) A common mitochondrial DNA variant associated with susceptibility to dilated cardiomyopathy in two different populations. Lancet (London, England) 357(9264). https:\/\/doi.org\/10.1016\/S0140-6736(00)04422-6","DOI":"10.1016\/S0140-6736(00)04422-6"},{"key":"10302_CR26","doi-asserted-by":"publisher","unstructured":"Candy GP, Skudicky D, Mueller UK, Woodiwiss AJ, Sliwa K, Luker F et al (1999) Association of left ventricular systolic performance and cavity size with angiotensin-converting enzyme genotype in idiopathic dilated cardiomyopathy. The American journal of cardiology 83(5). https:\/\/doi.org\/10.1016\/s0002-9149(98)00981-3","DOI":"10.1016\/s0002-9149(98)00981-3"},{"key":"10302_CR27","doi-asserted-by":"publisher","unstructured":"Tiago AD, Badenhorst D, Skudicky D, Woodiwiss AJ, Candy GP, Brooksbank R et al (2002) An aldosterone synthase gene variant is associated with improvement in left ventricular ejection fraction in dilated cardiomyopathy. Cardiovasc Res 54(3). https:\/\/doi.org\/10.1016\/s0008-6363(02)00281-x","DOI":"10.1016\/s0008-6363(02)00281-x"},{"key":"10302_CR28","doi-asserted-by":"publisher","unstructured":"Bailly C, Henriques S, Tsabedze N, Krause A (2019) Role of family history and clinical screening in the identification of families with idiopathic dilated cardiomyopathy in Johannesburg, South Africa. S Afr Med J 109(9). https:\/\/doi.org\/10.7196\/SAMJ.2019.v109i9.13936","DOI":"10.7196\/SAMJ.2019.v109i9.13936"},{"key":"10302_CR29","doi-asserted-by":"publisher","unstructured":"Brown CA, Lanning RW, Mckinney KQ, Salvino AR, Cherniske E, Crowe CA et al (2001) Novel and recurrent mutations in lamin A\/C in patients with Emery-Dreifuss muscular dystrophy. Am J Med Genet 102(4). https:\/\/doi.org\/10.1002\/ajmg.1463","DOI":"10.1002\/ajmg.1463"},{"key":"10302_CR30","doi-asserted-by":"publisher","unstructured":"Dec GW, Fuster V (1994) Idiopathic dilated cardiomyopathy. New England Journal of Medicine 331(23). https:\/\/doi.org\/10.1056\/NEJM199412083312307","DOI":"10.1056\/NEJM199412083312307"},{"key":"10302_CR31","doi-asserted-by":"publisher","unstructured":"Lakdawala NK, Winterfield JR, Funke BH (2013) Dilated cardiomyopathy. Circ Arrhythm Electrophysiol 6(1). https:\/\/doi.org\/10.1161\/CIRCEP.111.962050","DOI":"10.1161\/CIRCEP.111.962050"},{"key":"10302_CR32","doi-asserted-by":"publisher","unstructured":"Merlo M, Cannata A, Gobbo M, Stolfo D, Elliott PM, Sinagra G (2018) Evolving concepts in dilated cardiomyopathy. Eur J Heart Fail 20(2). https:\/\/doi.org\/10.1002\/ejhf.1103","DOI":"10.1002\/ejhf.1103"},{"key":"10302_CR33","doi-asserted-by":"publisher","unstructured":"Japp AG, Gulati A, Cook SA, Cowie MR, Prasad SK (2016) The diagnosis and evaluation of dilated cardiomyopathy. J Am Coll Cardiol 67(25). https:\/\/doi.org\/10.1016\/j.jacc.2016.03.590","DOI":"10.1016\/j.jacc.2016.03.590"},{"key":"10302_CR34","doi-asserted-by":"publisher","unstructured":"Murtaza G, Virk HUH, Khalid M, Rahman Z, Sitwala P, Schoondyke J et al (2017) Role of speckle tracking echocardiography in dilated cardiomyopathy: a review. Cureus 9(6). https:\/\/doi.org\/10.7759\/cureus.1372","DOI":"10.7759\/cureus.1372"},{"key":"10302_CR35","doi-asserted-by":"publisher","unstructured":"Gardner RS, Ozalp F, Murday AJ, Robb SD, Mcdonagh TA (2003) N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24(19). https:\/\/doi.org\/10.1016\/j.ehj.2003.07.005","DOI":"10.1016\/j.ehj.2003.07.005"},{"key":"10302_CR36","doi-asserted-by":"publisher","unstructured":"Kim H, Cho YK, Jun DH, Nam CW, Han SW, Hur SH et al (2008) Prognostic implications of the NT-ProBNP level and left atrial size in non-ischemic dilated cardiomyopathy. Circ J 72(10). https:\/\/doi.org\/10.1253\/circj.cj-07-1087","DOI":"10.1253\/circj.cj-07-1087"},{"key":"10302_CR37","doi-asserted-by":"publisher","unstructured":"Mcdonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M et al (2021)\u00a02021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36). https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"10302_CR38","doi-asserted-by":"publisher","unstructured":"Becker MaJ, Cornel JH, Van De Ven PM, Van Rossum AC, Allaart CP, Germans T (2018) The prognostic value of late\u00a0gadolinium-enhanced cardiac\u00a0magnetic\u00a0resonance imaging in\u00a0nonischemic dilated cardiomyopathy: a review and meta-analysis. JACC Cardiovasc Imaging 11(9). https:\/\/doi.org\/10.1016\/j.jcmg.2018.03.006","DOI":"10.1016\/j.jcmg.2018.03.006"},{"key":"10302_CR39","doi-asserted-by":"publisher","unstructured":"Di Marco A, Anguera I, Schmitt M, Klem I, Neilan TG, White JA et al (2017) Late Gadolinium enhancement and the\u00a0risk for ventricular arrhythmias or sudden\u00a0death in dilated cardiomyopathy: systematic review and meta-analysis. JACC Heart Fail 5(1). https:\/\/doi.org\/10.1016\/j.jchf.2016.09.017","DOI":"10.1016\/j.jchf.2016.09.017"},{"key":"10302_CR40","doi-asserted-by":"publisher","unstructured":"Pi SH, Kim SM, Choi JO, Kim EK, Chang SA, Choe YH et al (2018) Prognostic value of myocardial strain and late gadolinium enhancement on cardiovascular magnetic resonance imaging in patients with idiopathic dilated cardiomyopathy with moderate to severely reduced ejection fraction. J Cardiovasc Magn Reson 20(1). https:\/\/doi.org\/10.1186\/s12968-018-0466-7","DOI":"10.1186\/s12968-018-0466-7"},{"key":"10302_CR41","doi-asserted-by":"publisher","unstructured":"Zhang K, Wang W, Zhao S, Katz SD, Iervasi G, Gerdes AM et al (2018) Long-term prognostic value of combined free triiodothyronine and late gadolinium enhancement in nonischemic dilated cardiomyopathy. Clin Cardiol 41(1). https:\/\/doi.org\/10.1002\/clc.22858","DOI":"10.1002\/clc.22858"},{"key":"10302_CR42","doi-asserted-by":"publisher","unstructured":"Seferovic PM, Tsutsui H, Mcnamara DM, Ristic AD, Basso C, Bozkurt B et al (2021) Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society position statement on endomyocardial biopsy. J Card Fail 27(7). https:\/\/doi.org\/10.1016\/j.cardfail.2021.04.010","DOI":"10.1016\/j.cardfail.2021.04.010"},{"key":"10302_CR43","doi-asserted-by":"publisher","unstructured":"Evans JP, Skrzynia C, Burke W (2001) The complexities of predictive genetic testing. BMJ 322(7293). https:\/\/doi.org\/10.1136\/bmj.322.7293.1052","DOI":"10.1136\/bmj.322.7293.1052"},{"key":"10302_CR44","doi-asserted-by":"publisher","unstructured":"Hershberger RE, Givertz MM, Ho CY, Judge DP, Kantor PF, Mcbride KL et al (2018) Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med 20(9). https:\/\/doi.org\/10.1038\/s41436-018-0039-z","DOI":"10.1038\/s41436-018-0039-z"},{"key":"10302_CR45","doi-asserted-by":"publisher","unstructured":"Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC et al (2016) Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation. 134(23). https:\/\/doi.org\/10.1161\/CIR.0000000000000455","DOI":"10.1161\/CIR.0000000000000455"},{"key":"10302_CR46","doi-asserted-by":"publisher","unstructured":"Ramchand J, Wallis M, Macciocca I, Lynch E, Farouque O, Martyn M et al (2020) Prospective evaluation of the utility of whole exome sequencing in dilated cardiomyopathy. J Am Heart Assoc 9(2). https:\/\/doi.org\/10.1161\/JAHA.119.013346","DOI":"10.1161\/JAHA.119.013346"},{"key":"10302_CR47","doi-asserted-by":"publisher","unstructured":"Minoche AE, Horvat C, Johnson R, Gayevskiy V, Morton SU, Drew AP et al (2019) Genome sequencing as a first-line genetic test in familial dilated cardiomyopathy. Genet Med 21(3). https:\/\/doi.org\/10.1038\/s41436-018-0084-7","DOI":"10.1038\/s41436-018-0084-7"},{"key":"10302_CR48","doi-asserted-by":"publisher","unstructured":"Krause A (2019) New genetic testing technologies: advantages and limitations. S Afr Med J 109(4). https:\/\/doi.org\/10.7196\/SAMJ.2019.v109i4.13990","DOI":"10.7196\/SAMJ.2019.v109i4.13990"},{"key":"10302_CR49","doi-asserted-by":"publisher","unstructured":"Tschope C, Ammirati E, Bozkurt B, Caforio ALP, Cooper LT, Felix SB et al (2021) Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat Rev Cardiol 18(3). https:\/\/doi.org\/10.1038\/s41569-020-00435-x","DOI":"10.1038\/s41569-020-00435-x"},{"key":"10302_CR50","doi-asserted-by":"publisher","unstructured":"Horne BD, Rasmusson KD, Alharethi R, Budge D, Brunisholz KD, Metz T et al (2011) Genome-wide significance and replication of the chromosome 12p11.22 locus near the PTHLH gene for peripartum cardiomyopathy. Circ Cardiovasc Genet 4(4). https:\/\/doi.org\/10.1161\/CIRCGENETICS.110.959205","DOI":"10.1161\/CIRCGENETICS.110.959205"},{"key":"10302_CR51","doi-asserted-by":"publisher","unstructured":"Morales A, Painter T, Li R, Siegfried JD, Li D, Norton N et al (2010) Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation 121(20). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.931220","DOI":"10.1161\/CIRCULATIONAHA.109.931220"},{"key":"10302_CR52","doi-asserted-by":"publisher","unstructured":"Sheppard R, Hsich E, Damp J, Elkayam U, Kealey A, Ramani G et al (2016) GNB3 C825T Polymorphism and myocardial recovery in peripartum cardiomyopathy: results of the multicenter investigations of pregnancy-associated cardiomyopathy study. Circ Heart Fail 9(3). https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.115.002683","DOI":"10.1161\/CIRCHEARTFAILURE.115.002683"},{"key":"10302_CR53","doi-asserted-by":"publisher","unstructured":"Ware JS, Li J, Mazaika E, Yasso CM, Desouza T, Cappola TP et al (2016) Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med 374(3). https:\/\/doi.org\/10.1056\/NEJMoa1505517","DOI":"10.1056\/NEJMoa1505517"},{"key":"10302_CR54","doi-asserted-by":"publisher","unstructured":"Goli R, Li J, Brandimarto J, Levine LD, Riis V, Mcafee Q et al (2021) Genetic and phenotypic landscape of peripartum cardiomyopathy. Circulation 143(19). https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052395","DOI":"10.1161\/CIRCULATIONAHA.120.052395"},{"key":"10302_CR55","doi-asserted-by":"publisher","unstructured":"Verdonschot JaJ, Hazebroek MR, Ware JS, Prasad SK, Heymans SRB (2019) Role of targeted therapy in dilated cardiomyopathy: the challenging road toward a personalized approach. J Am Heart Assoc 8(11). https:\/\/doi.org\/10.1161\/JAHA.119.012514","DOI":"10.1161\/JAHA.119.012514"},{"key":"10302_CR56","doi-asserted-by":"publisher","unstructured":"Crasto S, My I, Di Pasquale E (2020) The Broad Spectrum of LMNA Cardiac diseases: from molecular mechanisms to clinical phenotype. Front Physiol 11. https:\/\/doi.org\/10.3389\/fphys.2020.00761","DOI":"10.3389\/fphys.2020.00761"},{"key":"10302_CR57","doi-asserted-by":"publisher","unstructured":"Ollila L, Nikus K, Holmstrom M, Jalanko M, Jurkko R, Kaartinen M et al (2017) Clinical disease presentation and ECG characteristics of LMNA mutation carriers. Open Heart 4(1). https:\/\/doi.org\/10.1136\/openhrt-2016-000474","DOI":"10.1136\/openhrt-2016-000474"},{"key":"10302_CR58","doi-asserted-by":"publisher","unstructured":"Repetti GG, Toepfer CN, Seidman JG, Seidman CE (2019) Novel therapies for prevention and early treatment of cardiomyopathies. Circ Res 124(11). https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.313569","DOI":"10.1161\/CIRCRESAHA.119.313569"},{"key":"10302_CR59","unstructured":"Pfizer (2021) A study of ARRY-371797 (PF-07265803) in patients with symptomatic dilated cardiomyopathy due to a lamin A\/C gene mutation.\u00a0Available from: https:\/\/www.pfizerclinicaltrials.com\/find-a-trial\/nct03439514."},{"key":"10302_CR60","doi-asserted-by":"publisher","unstructured":"Kraus SM, Shaboodien G, Francis V, Laing N, Cirota J, Chin A et al (2021) Rationale and design of the African Cardiomyopathy and Myocarditis Registry Program: the IMHOTEP study. Int J Cardiol 333. https:\/\/doi.org\/10.1016\/j.ijcard.2021.02.026","DOI":"10.1016\/j.ijcard.2021.02.026"},{"key":"10302_CR61","doi-asserted-by":"publisher","unstructured":"Peprah E, Wiley K, Sampson U, Narula J (2017) A New Age for African-Driven Genomics Research: Human Heredity and Health in Africa (H3Africa). Glob Heart 12(2). https:\/\/doi.org\/10.1016\/j.gheart.2017.05.003","DOI":"10.1016\/j.gheart.2017.05.003"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10302-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-023-10302-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-023-10302-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T20:43:02Z","timestamp":1687552982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-023-10302-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,14]]},"references-count":61,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["10302"],"URL":"https:\/\/doi.org\/10.1007\/s10741-023-10302-9","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,14]]},"assertion":[{"value":"15 February 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval waived since the article is a narrative review that does not contain identifiable patient data. However, the data depicted in Fig.\u00a0 was collected as part of \u201cThe Genetics of idiopathic dilated cardiomyopathy in Johannesburg Study\u201d. The study complied with the Declaration of Helsinki, and informed consent was obtained from the study participants. Approval to conduct the study was granted by the University of the Witwatersrand Human Research Ethics Committee (Ethics Clearance certificate number: M150467).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"NT is a cardiologist and has received consultation fees from Acino Health Care Group, \nAstraZeneca, Boston Scientific, Novartis Pharmaceuticals, Novo Nordisk, Pfizer, Sanofi, \nPhillips, Servier, Takeda, and Merck. He has also received educational and travel grants from \nMedtronic, Biotronik, Boston Scientific, and Vertice Health Care Group. None of the other \nauthors has any relevant financial or professional disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}